Overview

Topical Ruxolitinib for the Treatment of Vitiligo

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.
Phase:
Phase 2
Details
Lead Sponsor:
Tufts Medical Center